Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18828251 | 1.00 | TRPM8 (0.50) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL14189736 | 1.00 | TRPM8 (0.50) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL14189731 | 1.00 | TRPM8 (0.50) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL233023 | 1.00 | TRPM8 (0.50) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL17852174 | 0.93 | TRPM8 (0.46) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL1196048 | 0.90 | TRPM8 (0.43) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL14465136 | 0.90 | TRPM8 (0.47) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL18828250 | 0.90 | TRPM8 (0.47) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL14465134 | 0.89 | TRPM8 (0.43) | TRPM8PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL1196053 | 0.89 | TRPM8 (0.42) | TRPM8PPM1BPTPN1PPP1CCMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | TRPM8 1964/4885PPM1B 3025/4885PTPN1 909/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | TRPM8 1929/4885PPM1B 3053/4885PTPN1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.